Targeting clusterin in prostate cancer

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 9, 2008, Pages 265-274

  Rizzi, F ^a,b   Bettuzzi, Saverio ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Antisense oligonucleotide (ASO); Clusterin; Prostate cancer

Indexed keywords

CLUSTERIN; DOCETAXEL; MESSENGER RNA; OGX 011; ANTINEOPLASTIC AGENT; ISOPROTEIN;

ALTERNATIVE RNA SPLICING; APOPTOSIS; CANCER CELL; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; ANIMAL; DRUG DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; MALE; METABOLISM; PATHOPHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLUSTERIN; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 64049098527     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 2000; 25: 95-98. (Pubitemid 30122416)
2. Shannan B, Seifert M, Leskov K, et al. Challenges and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006; 13: 12-19.
3. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27: 633-645.
4. Trougakos IP, Gonos ES. Clusterin/Apolipoprotein J in human ageing and cancer. Int J Biochem Cell Biol 2002; 34: 1430-1448.
5. Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 1983; 258: 7714-7720.
6. Fritz IB, Burdzy K, Setchell B, Blaschuk O. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interaction in vitro. Biol Reprod 1983; 28: 1173-1180.
7. de Silva HV, Stuart WD, Park YB, et al. Purification and characterization of apolipoprotein J. J Biol Chem 1990; 265: 14292-14297. (Pubitemid 20281803)
8. Fischer-Colbrie R, Schachinger M, Zangerle R, Winkler H. Isolation and immunological characterization of a glycoprotein from adrenal chromaffine granules: isolation and carbohydrate analysis. J Neurochem 1984; 42: 1008-1016.
9. Choi NH, Mazda T, Tomita M. A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Mol Immun 1989; 26: 159-163. (Pubitemid 19249460)
10. James RW, Hochstrasser AC, Borghini I, Martini B, Pometta D, Hochstrasser D. Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arterioscler Tromb 1991; 11: 645-652.
11. Cochrane DR, Wang Z, Muramaki M, Gleave ME, Nelson CC. Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem 2007; 282: 2278-2287. (Pubitemid 47076744)
12. Andersen CL, Shepeler T, Thorsen K, et al Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics 2007; 23: 1039-1048. (Pubitemid 47019405)
13. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003; 278:11590-11600. (Pubitemid 36792721)
14. Lee C, Atanelov L, Modrek B, Xing Y. ASAP: the Alternative Splicing Annotation Project. Nucleic Acids Research 2003; 31: 101-105. (Pubitemid 36150344)
15. Yang CR, Leskov K, Hosley-Ebedein K, et al. Nuclear clusterin/XIP8, an X-ray induced Ku70-binding protein that signals cell death. Nucleic Acids Res 2000; 97: 5907-5912. (Pubitemid 30367497)
16. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004; 23: 2298-2304. (Pubitemid 38496784)
17. Caccamo AE, Scaltriti M, Caporali A, et al. Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Ann N Y Acad Sci 2003; 1010: 514-519. (Pubitemid 38265036)
18. 2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 2005; 12: 101-104.
19. Caccamo AE, Scaltritri M, Caporali A, et al. Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a45 kDa nuclear isoform of clusterin. Biochem J 2004; 382: 157-168. (Pubitemid 39141577)
20. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res 2004; 64: 6174-6182. (Pubitemid 39129419)
21. Zhang Q, Zhou W, Kundu S, et al. The leader sequence triggers and enhances several functions of clusterin and is instrumental of human prostate cancer in vivo and in vitro. BJU International 2006; 98: 452-460.
22. Moretti RM, Marelli MM, Mai S, et al. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res 2007; 67: 10325-10333. (Pubitemid 350070807)
23. Pajak B, Orzechowski A. Ethylenediaminetetraacetic acid affects subcellular expression of clusterin protein in human colon adenocarcinoma COLO 205 cell line. Anti-Cancer Drug 2007: 18: 55-63.
24. Choi-Miura NH, Takahashi Y, Nakano Y, Tobe T, Tomita M. Identification of the disulfide bonds in human plasma protein SP-40, (Apolipoprotein J). J Biochem 1992; 112: 557-561.
25. Thomas-Tikhonenko, A., Viard-Leveugle, I., Dews, M., et al. Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res 2004; 64: 3126-3136. (Pubitemid 38581413)
26. Xie MJ, Motoo Y, Su SB, et al. Expression of Clusterin in human pancreatic cancer. Pancreas 2002; 25: 234-238.
27. Santilli, G; Aronow, BJ; Sala, A. Essential requirement of apolipoprotein J (clusterin) signaling for IkB expression and regulation of NF-kB activity. J Biol Chem 2003; 278: 38214-38219. (Pubitemid 37221710)
28. Zhang LY, Ying WT, Mao YS, et al. Loss of Clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003; 9: 650-654. (Pubitemid 36531532)
29. Redondo M, Villar E, Torres-Munoz J, Tellez T Morell M, Petito CK. Overexpression of Clusterin in human breast carcinoma. Am J Pathol 2000; 157. 393-399. (Pubitemid 30626904)
30. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res 2004; 64: 7412-7419. (Pubitemid 39372082)
31. Bettuzzi S, Davalli P, Astancolle S, et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein-2) in human prostate cancer specimens. Cancer Res 2000; 60: 28-34. (Pubitemid 30058724)
32. Scaltriti M, Brausi M, Amorosi A, et al. Clusterin (SGP-2, ApoJ) expression is down-regulated in low and high grade human prostate cancer. Int J Cancer 2004; 108: 23-30. (Pubitemid 37444439)
33. Pins MR, Fiadjoe JE, Korley F, et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis 2004; 7: 243-248. (Pubitemid 41741511)
34. July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179-188. (Pubitemid 34137445)
35. Rauhala HE, Porkka KP, Saramaki OR, Tammela TLJ, Visakorpi T. Clusterin is epigenetically regulated in prostate cancer. Int J Cancer 2008; 123: 1601-1609.
36. Lund P, Weibhaupt K, Mikeska T, et al. Oncogenic HRAS suppress clusterin expression trough promoter hypermetilation. Oncogene 2006; 25: 4890-4903. (Pubitemid 44201180)
37. Hellebrekers DMEI, Melotte V, Vire E, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 2007; 67: 4138-4148. (Pubitemid 46815059)
38. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179-188. (Pubitemid 34137445)
39. Gleave ME, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005; 23: 38-46. (Pubitemid 40430679)
40. Trougakos IP, Gonos ES. Clusterin/Apolipoprotein J in human aging cancer. Int J Bioch Cell Biol 2002; 34: 1430-1448. (Pubitemid 35245400)
41. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004; 64: 1834-1842. (Pubitemid 38428709)
42. Sallman DA, Chen X, Zhong B, et al. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther 2007; 6: 2938-2947 (Pubitemid 350206772)
43. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2′methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. J Clin Oncol, Proceedings of American Society of Clinical Oncology, 2004.
44. Miyake H, Chi K, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6: 1655-1663. (Pubitemid 30305057)
45. So A, Sinnemann S, Huntsman D, Fazli L, Gleave ME. Knockdown of the cytoprotective chaperone, Clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005; 4: 1837-1849. (Pubitemid 43056967)
46. Gleave ME, Jansen B Clusterin and IGFBPs as antisense targets in prostate cancer. Ann NY Acad Sci 2003; 1002: 95-104. (Pubitemid 38253334)
47. Gleave ME, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005; 23: 38-46. (Pubitemid 40430679)
48. Caporali A, Davalli P, Astancolle S, et al. The chemopreventative action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin-over-expression. Carcinogenesis 2004; 25: 2217-2224. (Pubitemid 39534860)
49. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechin in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report froma one-year proof of principle study. Cancer Res 2006; 66: 1234-1240. (Pubitemid 43165995)
50. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008; Apr 4. [Epub ahead of print]